Literature DB >> 28889086

The Notch-3 receptor: A molecular switch to tumorigenesis?

Shakeel Inder1, Sinead O'Rourke2, Niamh McDermott2, Rustom Manecksha3, Stephen Finn4, Thomas Lynch3, Laure Marignol5.   

Abstract

The Notch pathway is a highly conserved pathway increasingly implicated with the progression of human cancers. Of the four existing receptors associated with the pathway, the deregulation in the expression of the Notch-3 receptor is associated with more aggressive disease and poor prognosis. Selective targeting of this receptor has the potential to enhance current anti-cancer treatments. Molecular profiling strategies are increasingly incorporated into clinical decision making. This review aims to evaluate the clinical potential of Notch-3 within this new era of personalised medicine.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cancer; Notch

Mesh:

Substances:

Year:  2017        PMID: 28889086     DOI: 10.1016/j.ctrv.2017.08.011

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  8 in total

1.  hsa_circ_0001741 promotes esophageal squamous cell carcinoma stemness, invasion and migration by sponging miR-491-5p to upregulate NOTCH3 expression.

Authors:  Lin Li; Kai Lei; Yingcheng Lyu; Binghua Tan; Ruihao Liang; Duoguang Wu; Kefeng Wang; Wenjian Wang; Huayue Lin; Minghui Wang
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 2.  Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach.

Authors:  Caio Bezerra Machado; Leidivan Sousa da Cunha; Jersey Heitor da Silva Maués; Flávia Melo Cunha de Pinho Pessoa; Marcelo Braga de Oliveira; Rodrigo Monteiro Ribeiro; Germison Silva Lopes; Manoel Odorico de Moraes Filho; Maria Elisabete Amaral de Moraes; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Int J Mol Sci       Date:  2022-05-14       Impact factor: 6.208

3.  A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.

Authors:  Lee S Rosen; Robert Wesolowski; Raffaele Baffa; Kai-Hsin Liao; Steven Y Hua; Brenda L Gibson; Steven Pirie-Shepherd; Anthony W Tolcher
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.651

Review 4.  Role of Notch Receptors in Hematologic Malignancies.

Authors:  Laura Gragnani; Serena Lorini; Silvia Marri; Anna Linda Zignego
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

5.  PIM-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion.

Authors:  Sebastian K J Landor; Niina M Santio; William B Eccleshall; Valeriy M Paramonov; Ellen K Gagliani; Daniel Hall; Shao-Bo Jin; Käthe M Dahlström; Tiina A Salminen; Adolfo Rivero-Müller; Urban Lendahl; Rhett A Kovall; Päivi J Koskinen; Cecilia Sahlgren
Journal:  J Biol Chem       Date:  2021-03-26       Impact factor: 5.157

6.  GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis.

Authors:  Heng Lin; Peng Hu; Hongyu Zhang; Yong Deng; Zhiqing Yang; Leida Zhang
Journal:  Mol Cells       Date:  2022-05-31       Impact factor: 5.034

Review 7.  Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products.

Authors:  Esra Küpeli Akkol; Hilal Bardakci; Timur Hakan Barak; Michael Aschner; Gökçe Şeker Karatoprak; Haroon Khan; Yaseen Hussain
Journal:  Oxid Med Cell Longev       Date:  2022-08-16       Impact factor: 7.310

8.  Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.

Authors:  Tim Wilhelmi; Xingbo Xu; Xiaoying Tan; Melanie S Hulshoff; Sabine Maamari; Samuel Sossalla; Michael Zeisberg; Elisabeth M Zeisberg
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.